Ramucirumab in metastatic colorectal cancer: Evidence to date and place in therapy

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 3, 2016, Pages 230-242

  Verdaguer, Helena ^a   Tabernero, Josep ^a   Macarulla, Teresa ^b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

angiogenesis; colorectal cancer; metastatic; ramucirumab; vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; RAMUCIRUMAB;

ANGIOGENESIS; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG MECHANISM; HUMAN; METASTATIC COLORECTAL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84968928008     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016635888     Document Type: Review

References (42)

1. Bennouna J., Sastre J., Arnold D., Österlund P., Greil R., Van Cutsem E., et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (Ml18147): a randomised phase III trial. Lancet Oncol 14: 29-37.
2. Bruns C., Liu W., Davis D., Shaheen R., McConkey D., Wilson M., et al. (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89: 488-499.
3. Bruns C., Shrader M., Harbison M., Portera C., Solorzano C., Jauch K., et al. (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102: 101-108.
4. Chen D., Wei L., Yu J., Zhang L., (2014) Regorafenib inhibits colorectal tumor growth through puma-mediated apoptosis. Clin Cancer Res 20: 3472-3484.
5. Chiorean E., Hurwitz H., Cohen R., Schwartz J., Dalal R., Fox F., et al. (2015) Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol 26: 1230-1237.
6. Ciardiello F., Lenz H., Kohne C., Heinemann V., Tejpar S., Melezinek I., et al. (2014) Treatment outcome according to tumor RAS mutation status in crystal study patients with metastatic colorectal cancer (MCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol (ASCO Annual Meeting) 32: abstr 3506.
7. Douillard J., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 28: 4697-4705.
8. Ellis L., Liu W., Wilson M., (1996) Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery 120: 871-878.
9. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. (2012) Globocan 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. Lyon, France: International Agency for Research on Cancer.
10. Ferrara N., (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
11. Ferrara N., Gerber H., Lecouter J., (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
12. Ferrara N., Hillan K., Novotny W., (2005) Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335.
13. Folkman J., (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3: 643-651.
14. Garcia-Carbonero R., Obermannova R., Bodoky G., Prausova J., Ciuleanu T., García Alfonso P., et al. (2015) Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Ann Oncol 26: 115.
15. Garcia-Carbonero R., Rivera F., Maurel J., Ayoub J., Moore M., Cervantes A., et al. (2014) An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 19: 350-351.
16. Giantonio B., Catalano P., Meropol N., O'Dwyer P., Mitchell E., Alberts S., et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25: 1539-1544.
17. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381: 303-312.
18. Hanahan D., Weinberg R., (2000) The hallmarks of cancer. Cell 100: 57-70.
19. Hicklin D., Ellis L., (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
20. Holash J., Davis S., Papadopoulos N., Croll S., Ho L., Russell M., et al. (2002) VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99: 11393-11398.
21. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
22. Jimenez X., Lu D., Brennan L., Persaud K., Liu M., Miao H., et al. (2005) A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 4: 427-434.
23. Kerbel R., (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
24. Klement G., Huang P., Mayer B., Green S., Man S., Bohlen P., et al. (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8: 221-232.
25. Lee J., Chow N., Wang S., Huang S., (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753.
26. Matthews W., Jordan C., Gavin M., Jenkins N., Copeland N., Lemischka I., (1991) A receptor isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to C-kit. Proc Natl Acad Sci USA 88: 9026-9030.
27. National Cancer Institute (NCI). (2015) SEER Stat Fact Sheets: Colon and Rectum Cancer. Available at: http://seer.cancer.gov/statfacts/html/colorect.html (. accessed September 2015).
28. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K., (2000) Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156: 1499-1504.
29. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., et al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218.
30. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., et al. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (FLT) closely related to the fms family. Oncogene 5: 519-524.
31. Spratlin J., Cohen R., Eadens M., Gore L., Camidge D., Diab S., et al. (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28: 780-787.
32. Strumberg D., Schultheis B., (2012) Regorafenib for cancer. Expert Opin Investig Drugs 21: 879-889.
33. Sweeney P., Karashima T., Kim S., Kedar D., Mian B., Huang S., et al. (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8: 2714-2724.
34. Tabernero J., Yoshino T., Cohn A., Obermannova R., Bodoky G., Garcia-Carbonero R., et al. (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase III study. Lancet Oncol 16: 499-508.
35. Takahashi Y., Kitadai Y., Bucana C., Cleary K., Ellis L., (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968.
36. Tonra J., Deevi D., Corcoran E., Li H., Wang S., Carrick F., et al. (2006) Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12: 2197-2207.
37. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237.
38. Van Cutsem E., Cervantes A., Nordlinger B., Arnold D., (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: 1-9.
39. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506.
40. Witte L., Hicklin D., Zhu Z., Pytowski B., Kotanides H., Rockwell P., et al. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (FLK1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17: 155-161.
41. Yoshino T., Yamazaki K., Gotoh M., Nasroulah F., Gao L., Yoshizuka N., et al. (2015) Safety and pharmacokinetics of second-line ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma. Anticancer Res 35: 4003-4007.
42. Zhu Z., Bohlen P., Witte L., (2002) Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2: 135-156.